Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Diehl

Showing results (1-10 of 180) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2003
Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's diseaseVolker Diehl
Nature Reviews. Clinical Oncology|June 3, 2010
Hematology. Are macrophages the bad guys in Hodgkin lymphoma?Volker Diehl
Hematology. American Society of Hematology. Education Program|December 17, 2009
The bridge between patient and doctor: the shift from CAM to integrative medicineVolker Diehl
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Advanced Hodgkin's disease: ABVD is better, yet is not good enough!Volker Diehl
The New England Journal of Medicine|November 9, 2007
Hodgkin's disease--from pathology specimen to cureVolker Diehl
Hematology/Oncology Clinics of North America|November 30, 2013
Hematology/Oncology Clinics of North America. Hodgkin lymphoma. PrefaceVolker Diehl, Peter Borchmann
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|August 24, 2007
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?Volker Diehl, Michael Fuchs,
Current Treatment Options in Oncology|August 29, 2003
Current treatment strategies in early stage Hodgkin's diseaseAndreas Josting, Volker Diehl
Hematology/Oncology Clinics of North America|November 30, 2013
First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasmsHarald Stein, Volker Diehl
Nature Clinical Practice. Oncology|May 10, 2006
Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?Volker Diehl, Andreas Engert
Pageof 18

Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2003
Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's diseaseVolker Diehl
Nature Reviews. Clinical Oncology|June 3, 2010
Hematology. Are macrophages the bad guys in Hodgkin lymphoma?Volker Diehl
Hematology. American Society of Hematology. Education Program|December 17, 2009
The bridge between patient and doctor: the shift from CAM to integrative medicineVolker Diehl
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Advanced Hodgkin's disease: ABVD is better, yet is not good enough!Volker Diehl
The New England Journal of Medicine|November 9, 2007
Hodgkin's disease--from pathology specimen to cureVolker Diehl
Hematology/Oncology Clinics of North America|November 30, 2013
Hematology/Oncology Clinics of North America. Hodgkin lymphoma. PrefaceVolker Diehl, Peter Borchmann
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|August 24, 2007
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?Volker Diehl, Michael Fuchs,
Current Treatment Options in Oncology|August 29, 2003
Current treatment strategies in early stage Hodgkin's diseaseAndreas Josting, Volker Diehl
Hematology/Oncology Clinics of North America|November 30, 2013
First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasmsHarald Stein, Volker Diehl
Nature Clinical Practice. Oncology|May 10, 2006
Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?Volker Diehl, Andreas Engert
Pageof 18